Incyte Corporation ($INCY) Stock Forecast: Down 7.0% Today

What is Incyte Corporation?

INCY is the ticker symbol for Incyte Corporation, a biopharmaceutical company known for its lead drug Jakafi and Opzelura cream. The company recently reported mixed fourth-quarter 2025 results, with a revenue beat but an earnings miss, leading to a bearish movement in the stock.

Why is Incyte Corporation going down?

INCY stock is down 7.0% on Feb 10, 2026 20:01

• Incyte Corporation's stock experienced a bearish movement after reporting mixed Q4 2025 results, with a revenue beat but an earnings miss.
• Despite strong sales growth, including significant increases in Jakafi and Opzelura sales, the company's adjusted EPS fell short of expectations due to higher operating expenses.
• The market reaction indicates that investors were more focused on the earnings miss rather than the revenue beat, leading to a decline in the stock price.
• Analysts maintaining a Hold rating on the stock and highlighting upcoming pipeline readouts and commercial execution as key focuses suggest a cautious outlook on the company's performance in 2026.

INCY Price Chart

INCY Technical Analysis

INCY News

Why Incyte (INCY) Stock Is Nosediving

Shares of Incyte Corporation (NASDAQ:INCY) fell 8.8% after the biopharmaceutical company reported mixed fourth-quarter 2025 results. A significant revenue beat was overshadowed by an earnings miss, with adjusted EPS falling short of Wall Street's consensus. Additionally, the company's operating margin contracted, indicating increased expenses.

https://finviz.com/news/306159/why-incyte-incy-stock-is-nosediving

INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales

Incyte Corporation (INCY) reported mixed Q4 2025 results, with adjusted earnings missing estimates but total revenues exceeding expectations due to strong product sales. The company's lead drug, Jakafi, and Opzelura cream were key drivers of revenue growth, along with new drug Zynyz. Despite the revenue beat, higher operating expenses led to the earnings miss, causing a slight dip in Incyte's pre-market shares.

https://finviz.com/news/306065/incy-q4-earnings-miss-estimates-revenues-beat-on-higher-product-sales

Incyte slips after Q4 profit miss despite strong sales growth

Incyte (INCY) reported a Q4 profit miss, with adjusted earnings per share of $0.68, falling short of the $0.78 consensus. This was despite robust sales growth, including a 10% increase in Jakafi sales and 24% growth in Opzelura sales. The company also announced a new $2 billion share repurchase program.

https://www.msn.com/en-us/money/companies/incyte-slips-after-q4-profit-miss-despite-strong-sales-growth/ar-AA1W4ng4?ocid=finance-verthp-feeds

Incyte (NASDAQ:INCY) Delivers Unexpected Q4 CY2025 Revenue Results

Incyte Corporation (NASDAQ: INCY) reported stronger-than-expected Q4 2025 revenues of $1.51 billion, a 27.8% increase year-over-year, significantly beating analyst forecasts. However, its adjusted EPS of $1.80 fell short of projections by 6.1%. Despite the mixed results and a subsequent stock price drop of 3.8%, the company highlighted consistent revenue growth and positive long-term profitability trends.

https://www.bitget.com/amp/news/detail/12560605191501

Truist Securities reiterates Hold rating on Incyte stock, maintains $103 target

Truist Securities has reiterated its Hold rating for Incyte (NASDAQ: INCY) stock, maintaining a $103 price target. This decision follows Incyte's fiscal year 2026 net product revenue guidance of $4.77-4.94 billion, which aligns with consensus estimates, and a fourth-quarter earnings miss despite beating revenue expectations. The firm highlights upcoming pipeline readouts and commercial execution as key focuses for Incyte in 2026.

https://ng.investing.com/news/stock-market-news/truist-securities-reiterates-hold-rating-on-incyte-stock-maintains-103-target-93CH-2334245

Trending Today

Prime Medicine ($PRME) Stock Forecast: Down 5.1% Today

Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 5.2% Today

Unity Software ($U) Stock Forecast: Up 5.1% Today

Broadridge Financial Solutions Inc.Common Stock ($BR) Stock Forecast: Down 5.0% Today

Marriott International ($MAR) Stock Forecast: Up 8.8% Today

WESCO International, Inc. ($WCC) Stock Forecast: Down 6.8% Today

Masco Corporation ($MAS) Stock Forecast: Up 9.4% Today

Quest Diagnostics Incorporated ($DGX) Stock Forecast: Up 7.3% Today

IQVIA Holdings Inc. ($IQV) Stock Forecast: Down 5.2% Today

S&P Global Inc. ($SPGI) Stock Forecast: Down 9.7% Today

Incyte Corporation Price History

10.01.2026 - INCY Stock was down 5.3%

• Today, Incyte's stock (INCY) faced a bearish movement due to specific reasons:
• Despite surpassing revenue expectations for Q4 CY2025 at $1.51 billion, the company's non-GAAP profit of $1.80 per share fell short of analyst predictions, leading to investor dissatisfaction.
• The 2026 revenue forecast of $4.77 billion to $4.94 billion, which is conservative compared to current analyst consensus, along with heightened R&D and launch expenses affecting profitability, influenced the negative market outlook.
• Despite emphasizing significant core business growth and pipeline advancements, conflicting financial results and insider sales activity raised investor concerns and triggered a stock sell-off.
• Investors had anticipated more robust outcomes, especially in terms of profitability, resulting in a 4.4% pre-market trading decline.

10.01.2026 - INCY Stock was down 6.0%

• INCY reported a Q4 profit miss despite strong sales growth, leading to a negative market movement.
• The stock declined in pre-market trading due to concerns about the earnings per share miss, although revenue surpassed expectations.
• A Hold rating on INCY stock was reiterated by Truist Securities, highlighting upcoming pipeline readouts and commercial execution as significant areas of focus for the company in 2026.
• The company's conservative 2026 revenue guidance and increased R&D and launch costs impacting profitability were factors contributing to the pessimistic outlook on the stock.

10.01.2026 - INCY Stock was down 7.0%

• Incyte Corporation's stock experienced a bearish movement after reporting mixed Q4 2025 results, with a revenue beat but an earnings miss.
• Despite strong sales growth, including significant increases in Jakafi and Opzelura sales, the company's adjusted EPS fell short of expectations due to higher operating expenses.
• The market reaction indicates that investors were more focused on the earnings miss rather than the revenue beat, leading to a decline in the stock price.
• Analysts maintaining a Hold rating on the stock and highlighting upcoming pipeline readouts and commercial execution as key focuses suggest a cautious outlook on the company's performance in 2026.

07.00.2026 - INCY Stock was up 5.8%

• INCY is the ticker symbol for Incyte, a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The overall market today saw bullish movements, with the Dow and S&P 500 hitting record highs.
• ASSESSMENT:
• The bullish movement in INCY today can be attributed to the positive top-line results from its Phase III frontMIND study for Monjuvi/Minjuvi in combination with Bristol Myers’ Revlimid and R-CHOP for newly diagnosed DLBCL. This successful study meeting key goals and endpoints has likely boosted investor confidence in the company's pipeline and future prospects.
• Additionally, the exclusive license agreement with Prelude Therapeutics for the advanced clinical development of PRT2527 for oncology showcases strategic collaborations that can enhance the company's position in the market and expand its potential for growth.
• The upcoming submission of a supplemental biologics license application to the FDA for label expansion for first-line DLBCL treatment further indicates positive developments in the company's product portfolio, potentially attracting more investors seeking exposure to innovative treatments in the biopharmaceutical sector.

04.10.2025 - INCY Stock was up 9.1%

• The bullish movement in Incyte's stock is likely due to positive advancements in their partnership with Prelude Therapeutics for potential disease-modifying treatments and the company's robust financial performance in Q3, surpassing revenue expectations and demonstrating growth potential in the face of patent concerns. These factors, combining positive developments and financial success, probably boosted investor optimism and led to the stock's upward trajectory.

19.11.2025 - INCY Stock was up 5.0%

• The strong bullish movement in Incyte's stock today could be attributed to the positive quarterly results, beating analyst EPS and revenue estimates.
• The recent approval for Minjuvi in Europe, a chemotherapy-free immunotherapy for follicular lymphoma, has likely boosted investor confidence in Incyte's oncology portfolio.
• The significant insider selling by Incyte's EVP, Michael James Morrissey, might have initially raised concerns, but the overall market sentiment seems to have focused more on the company's recent achievements and future pipeline potential.
• Incyte's upcoming presentation at the J. P. Morgan Healthcare Conference could also be generating optimism among investors regarding the company's future outlook and growth prospects.

06.00.2026 - INCY Stock was up 4.1%

• Positive top-line data from its Phase III frontMIND trial for tafasitamab in combination with lenalidomide and R-CHOP met primary and key secondary endpoints, boosting investor confidence in the company's pipeline.
• Plans to submit a supplemental biologics license application for tafasitamab as a first-line therapy for DLBCL in 2026 signify potential future revenue streams and market expansion for Incyte.
• Analysts' caution about market share due to competitive landscape may present challenges, but the strong trial results have the potential to reshape Incyte's investment narrative and reduce its reliance on existing products like Jakafi.
• Overall, positive trial outcomes and future regulatory filings have spurred investor optimism and contributed to the bullish movement in Incyte's stock today.

08.11.2025 - INCY Stock was down 1.4%

• Today's downward movement in Incyte Corporation's stock could be linked to profit-taking by investors following a string of positive developments.
• In spite of recent upgrades and promising clinical data shared at a medical conference, the stock may have dipped as investors secured profits.
• The initial surge in stock price due to increased investments from institutional shareholders like American Century Companies Inc. and Invesco Ltd. might have been counterbalanced by subsequent selling pressure.
• The broader market sentiment towards biopharmaceutical firms and the healthcare industry could have also played a role in the stock's decline today.

06.01.2026 - INCY Stock was up 5.0%

• Increase in price target for Incyte to $110 from $102, along with other analysts adjusting their targets, has created a positive outlook for the stock, leading to a bullish movement.
• Expectations of a strong Q4 earnings report, driven by robust sales of its key drugs and a high probability of an earnings beat, have likely contributed to investor optimism.
• The positive opinion from CHMP of the EMA for Incyte's Zynyz in treating a rare cancer indication opens up new market opportunities, further boosting investor confidence in the company's growth potential.
• The upcoming earnings call on February 10 to unveil Q4 and full-year 2025 results adds anticipation and excitement among investors, fueling the bullish sentiment towards Incyte's stock.

07.00.2026 - INCY Stock was up 5.2%

• Positive Phase III trial results for tafasitamab in combination with lenalidomide and R-CHOP for DLBCL have significantly boosted investor confidence in Incyte's potential for a new treatment option in the oncology space.
• Strategic collaborations and exclusive license agreements with Prelude Therapeutics have reshaped Incyte's pipeline, indicating a promising future for the company's oncology programs.
• Despite analyst caution regarding market share due to a competitive landscape, the successful trial outcomes and plans for regulatory approval have propelled INCY stock to gain traction among investors, leading to today's bullish market movement.
• Overall, the optimistic news surrounding Incyte's clinical developments and strategic partnerships have fueled positive sentiment and contributed to the stock's upward momentum.

29.09.2025 - INCY Stock was up 7.2%

• Incyte Corporation demonstrated robust growth in third-quarter revenue, exceeding consensus estimates and displaying a 20% year-over-year increase in total revenues.
• The strong performance in Q3 was attributed to higher sales figures of key products like Jakafi, Opzelura, and recent launches, indicating positive revenue prospects for the company.
• Despite concerns regarding a patent expiration in 2028, the company's recent quarter results have bolstered investor confidence, resulting in a bullish market trend for INCY stock today.

08.00.2026 - INCY Stock was down 5.1%

• INCY stock experienced a strong bearish movement despite positive Phase 3 trial results for its lymphoma drug, Monjuvi/Minjuvi.
• The bearish movement could be attributed to profit-taking by investors after a significant run-up in the stock price following the positive trial results.
• The market may also be reacting to broader sector trends or macroeconomic factors impacting biotech stocks, leading to a temporary pullback in INCY's share price.
• It's essential for investors to consider the long-term growth potential of INCY, especially with promising developments in its pipeline and successful clinical trials, despite the short-term market volatility.